Stockreport

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Genenta Science S.p.A.  (GNTA) 
PDF MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today anno [Read more]